High-quality data have shown that it is rather the combination of DNMT3A mutation status and FLT3-ITD status that define prognosis; with wild-type DNMT3A, the presence of NRAS or FLT3-ITD mutations does not significantly affect the prognosis of NPM1m AML, whereas DNMT3A-mutated NPM1m AML shows distinctly unfavorable prognosis in the presence of FLT3-ITD (comparing to FLT3 wild-type cases) and favorable prognosis in the presence of NRAS mutations (comparing to NRAS wild-type cases) [11,41]. This evidence concerns the gene NRAS and acute myeloid leukemia.